Top Startup and Tech Funding News – April 15 2025

It’s Wednesday, April 15, 2026, and we’re back with today’s top startup and tech funding news. Today’s rounds highlight a clear shift toward AI infrastructure, agentic systems, next-generation therapeutics, and space-based intelligence. As capital continues to concentrate around platforms that can operate at scale—whether in compute, biology, or orbit—investors are backing companies that build the underlying systems powering decision-making, automation, and resilience across industries.

Large early-stage financings in biotech and cybersecurity point to growing confidence in platform-first approaches, while continued momentum in AI superclouds, autonomous driving, and enterprise decisioning signals a broader move from experimentation to deployment. At the same time, climate resilience, education, and medical devices are attracting targeted capital aimed at real-world impact. Today’s deals span AI, healthcare, space, climate, and consumer learning—reflecting a market that is doubling down on both digital intelligence and physical-world outcomes.

Tech Funding News

Funding Highlights

• Beeline Medicines raises $300M Series A for precision autoimmune and inflammatory drug development
• Terremoto Biosciences raises $108M Series C for selective AKT1 therapies in oncology and rare disease
• Turion Space raises $75M+ Series B for space domain awareness and orbital intelligence
• Artemis raises $70M Series A for AI-native security operations and automated response
• Wayve raises $60M Series D extension for hardware-agnostic autonomous driving AI
• Parasail raises $32M Series A for an AI supercloud for inference and training
• NanoTech Materials raises $29.4M Series A for extreme heat and wildfire infrastructure protection
• Hilbert raises $28M Series A for agentic AI that automates growth decisions
• Gizmo raises $22M Series A for AI-powered studying and personalized learning loops
• Sonire Therapeutics raises $18M Series A for focused ultrasound therapy in pancreatic cancer

Investor Activity

Today’s funding rounds drew a mix of venture firms and strategic backers doubling down on infrastructure-led opportunities across AI, biotech, and space. Firms like Andreessen Horowitz, Felicis, and Bain Capital supported platforms aimed at scaling decision-making and automation, while semiconductor leaders including AMD, Arm, and Qualcomm signaled continued alignment between AI software and hardware ecosystems. Across healthcare and life sciences, specialist investors such as RA Capital, OrbiMed, and Santé Ventures reinforced conviction in capital-intensive clinical platforms. Meanwhile, participation from industrial and real estate-linked investors highlights growing interest in climate resilience and physical infrastructure, pointing to a broader convergence between digital intelligence and real-world deployment.

Beeline Medicines Raises $300M Series A for Precision Autoimmune and Inflammatory Drug Development

Beeline Medicines is a clinical-stage biotech building a portfolio of mechanistically guided therapies for autoimmune and inflammatory diseases, anchored by a lupus program and additional in-licensed assets.

This financing matters because it provides an unusually large “day-one” capital base for an immunology-focused company while it pushes toward late-stage clinical development. In a category where clinical programs can require multi-year, multi-trial execution, the round meaningfully increases Beeline’s ability to run parallel development tracks rather than sequencing bets one at a time.

Funding Details:

• Startup: Beeline Medicines
• Investors: Bain Capital
• Amount Raised: $300M
• Total Raised: $300M
• Funding Stage: Series A
• Funding Date: April 15, 2026

Terremoto Biosciences Raises $108M Series C for Selective AKT1 Therapies in Oncology and Rare Disease

Terremoto is developing small-molecule medicines targeting AKT biology, including programs designed to improve selectivity and tolerability in pathways historically constrained by safety tradeoffs. The company has a lead candidate already in Phase 1 testing and another expected to enter the clinic for hereditary hemorrhagic telangiectasia.

The funding is significant because it extends investor conviction in a specific thesis: targeting disease-driving AKT isoforms while reducing off-target toxicity, which has limited prior approaches to the broader PI3K/AKT pathway. This round also reflects continued appetite for well-capitalized oncology platforms that can run clinical proof points quickly.

Funding Details:

• Startup: Terremoto Biosciences
• Investors: RA Capital Management; Deep Track Capital; Osage University Partners; BeOne Medicines; OrbiMed; Third Rock Ventures; Novo Holdings; Cormorant Asset Management
• Amount Raised: $108M
• Total Raised: $358M
• Funding Stage: Series C
• Funding Date: April 15, 2026

Turion Space Raises $75M+ Series B for Space Domain Awareness and Orbital Intelligence

Turion builds integrated spacecraft, sensors, and mission software for customers who need operational capabilities in orbit, with an emphasis on reconnaissance and space-domain awareness workflows.

This funding matters because it pairs scale capital with a defense-adjacent market tailwind: rising demand for persistent space-based sensing, faster satellite deployment cycles, and differentiated onboard-plus-ground software. Turion is also positioned to compete for work tied to a major Space Force supplier program, adding strategic relevance beyond the round itself.

Funding Details:

• Startup: Turion Space
• Investors: Washington Harbour Partners (lead); Aurelia Foundry; Forward Deployed VC; FoundersX; Center15 Capital; Magnetar; HOF Capital; Industrious Ventures
• Amount Raised: $75M+
• Total Raised: Not disclosed
• Funding Stage: Series B
• Funding Date: April 15, 2026

Artemis Raises $70M in Series A Funding for AI-Native Security Operations and Automated Response

Artemis is building an AI-native cybersecurity platform designed to detect and respond to attacks that unfold at machine speed, using organization-specific models of “normal” behavior across identity, cloud, applications, and endpoints to reduce alert noise and shorten time-to-containment.

The round is notable both for size and structure: Artemis disclosed $70 million across seed and Series A as it emerged from stealth, a signal that investors are increasingly underwriting “platform-scale” security plays earlier—especially those aimed at consolidating operational decisioning rather than adding another point tool.

Funding Details:

• Startup: Artemis
• Investors: Felicis (Series A lead); First Round Capital; Brightmind; Theory VC; Lockstep
• Amount Raised: $70M
• Total Raised: $70M
• Funding Stage: Series A
• Funding Date: April 15, 2026

Wayve Raises $60M in Series D Extension for Hardware-Agnostic Autonomous Driving AI

The London-based autonomous driving startup said Wednesday it secured $60 million in fresh funding from Qualcomm, AMD, and Arm Holdings, adding three of the industry’s most influential chipmakers to a cap table that already includes Nvidia.

Wayve develops end-to-end “embodied AI” driving software intended to generalize across vehicles and environments without relying on high-definition maps, with an explicit strategy to run on a broad range of automotive compute platforms.

This $60 million extension matters because it deepens the company’s alignment with the semiconductor stack that ultimately governs whether autonomous and assisted-driving software can scale across OEM programs. The round effectively adds silicon-level distribution leverage—capital plus integration pathways—at a time when autonomy programs are increasingly bottlenecked by compute choices and platform fragmentation.

Funding Details:

• Startup: Wayve
• Investors: Advanced Micro Devices; Arm; Qualcomm Ventures
• Amount Raised: $60M
• Total Raised: Not disclosed
• Funding Stage: Series D
• Funding Date: April 15, 2026

Parasail Raises $32M in Series A Funding for an AI Supercloud for Inference and Training

Parasail is building an “AI Supercloud” layer for deploying and scaling AI agents, positioning itself as an orchestration and optimization fabric across globally distributed compute resources. The AI startup announced today that it raised $32 million in Series A funding, bringing its total to $42 million. The round was co-led by Touring Capital and Kindred Ventures, with backing from Samsung NEXT, Flume Ventures, Banyan Ventures, and earlier investors.

This funding matters because the market is rapidly separating into two layers: model developers and the infrastructure/runtime layer that makes those models economically usable in production. Parasail is explicitly targeting that runtime layer—reducing inference and training friction in environments where cost, latency, and availability can determine whether an AI product is viable at scale.

• Startup: Parasail
• Investors: Touring Capital (co-lead); Kindred Ventures (co-lead); Samsung NEXT; Flume Ventures; Banyan Ventures
• Amount Raised: $32M
• Total Raised: $42M
• Funding Stage: Series A
• Funding Date: April 15, 2026

NanoTech Materials Raises $29.4M in Series A Funding for Extreme Heat and Wildfire Infrastructure Protection

NanoTech develops high-performance coatings designed to reduce heat transfer and enhance fire resilience in buildings and critical infrastructure, with products positioned for roof cooling, insulation, and wildfire mitigation. Today, the Texas-based advanced materials startup closed a $29.4 million Series A round led by HPI Real Estate & Investments, with participation from Goose Capital and Milliken & Company.

This financing matters because it targets a practical, infrastructure-adjacent wedge: retrofittable materials that can reduce energy loads while also hardening surfaces against climate-driven risks. The company plans to use the capital to scale manufacturing and accelerate commercialization into commercial, industrial, and government end markets.

Funding Details:

• Startup: NanoTech Materials
• Investors: HPI Real Estate & Investments (lead); Goose Capital; Milliken & Company
• Amount Raised: $29.4M
• Total Raised: $34.4M
• Funding Stage: Series A
• Funding Date: April 15, 2026

Hilbert Raises $28M in Series A Funding for Agentic AI That Automates Growth Decisions

Hilbert is developing agentic AI software that connects company data across teams into a single decisioning system, then structures that data so models can recommend actions and quantify their financial impact.

This funding matters because it reflects a broader enterprise shift: AI is moving from dashboards and insights toward systems that can recommend and operationalize actions with measurable ROI. Hilbert’s pitch targets that inflection point—helping teams turn fragmented data into decisions that can be executed repeatedly at scale.

Funding Details:

• Startup: Hilbert
• Investors: Andreessen Horowitz (lead)
• Amount Raised: $28M
• Total Raised: Not disclosed
• Funding Stage: Series A
• Funding Date: April 15, 2026

Gizmo Raises $22M in Series A Funding for AI-Powered Studying and Personalized Learning Loops

Gizmo is an AI-powered learning platform that turns user content (notes, documents, and web sources) into study materials like flashcards and quizzes, aiming to drive daily learning habits through engagement mechanics and social features.

The round matters because consumer learning apps rarely scale without institutional distribution or mandated usage. Gizmo is claiming organic traction across countries and is now using Series A capital to expand engineering and AI capacity while pushing deeper into the U.S. college market.

Funding Details:

• Startup: Gizmo
• Investors: Shine Capital (lead); Ada Ventures; Seek Investments; GSV; NFX
• Amount Raised: $22M
• Total Raised: $25.5M
• Funding Stage: Series A
• Funding Date: April 15, 2026

Sonire Therapeutics Raises $18M Series A for Focused Ultrasound Therapy in Pancreatic Cancer

Sonire Therapeutics is developing high-intensity focused ultrasound (HIFU) technology for noninvasive tumor ablation, with current efforts focused on pancreatic cancer and expanded U.S. clinical development. CEO Tohru Satoh told Axios today that the company raised $18 million in Series A funding to focus on ultrasound devices for pancreatic cancer treatment.

This funding matters because pancreatic cancer remains one of the deadliest major cancers, and device-based approaches that can be deployed without major surgery are drawing increased attention as complements to systemic therapies. The round of funds continued clinical progress and operational runway to reach the next major regulatory and trial milestones.

Funding Details:

• Startup: Sonire Therapeutics
• Investors: Santé Ventures (lead); Fast Track Initiative; Japan Growth Capital; SBI Investment
• Amount Raised: $18M
• Total Raised: $18M
• Funding Stage: Series A
• Funding Date: April 15, 2026

Tech Funding Summary Table

What today’s deals signal

Today’s funding mix shows a market still rewarding platform leverage—either through data/decision automation (Hilbert), infrastructure orchestration for AI runtimes (Parasail), or “AI-native” consolidation opportunities in cybersecurity (Artemis).

At the same time, two capital-intensive categories remain heavily funded when tied to strategic end markets: defense/space capabilities (Turion) and autonomy compute ecosystems (Wayve), where the “go-to-market” is inseparable from integration into hardware and procurement channels.

Biotech continues to attract outsized checks for programs that can plausibly reach meaningful clinical inflection points quickly—illustrated by Terremoto’s Series C and Beeline’s large Series A footprint—while medtech rounds like Sonire’s show sustained investor appetite for device-based oncology approaches when paired with clear clinical development plans.